Inovio Pharmaceuticals Reports Positive Data

Inovio Pharmaceuticals shares were up nearly 3% in pre-market trading after it said its Zika vaccine protected against Zika virus-induced damage to testes and sperm.

The company said the vaccine also prevented persistence of the virus in the reproductive tract of all vaccinated male mice challenged with a high dose of the Zika virus. Inovio is developing the vaccine, GLS-5700, with GeneOne Life Science, Inc., and academic collaborators from the U.S. and Canada. “This published data suggests another avenue of potential protection against the Zika virus,” said J. Joseph Kim, CEO of Inovio, adding that the “data suggests that our Zika vaccine may represent an opportunity to limit the potential for sexual transmission of the virus.”

Leave a Comment